A Study of Ivaltinostat Plus Capecitabine or Capecitabine in Metastatic Pancreatic Adenocarcinoma

Launched by CG PHARMACEUTICALS, INC · Feb 10, 2022

Keywords

ClinConnect Summary

This clinical trial is investigating a new treatment approach for patients with metastatic pancreatic adenocarcinoma, a type of cancer that has spread beyond the pancreas. The study is testing a drug called ivaltinostat combined with capecitabine, a standard chemotherapy medication, to see if this combination is safe and effective. Patients will be divided into two groups: one will receive both ivaltinostat and capecitabine, while the other group will receive only capecitabine. The goal is to determine the best dose of ivaltinostat and to evaluate how well the treatments work over several cycles of therapy.

To participate in this study, patients need to be at least 18 years old and must have previously received treatment for their cancer without evidence of disease progression. They should also be in relatively good health, as indicated by their performance status. Throughout the trial, participants will undergo regular check-ups to monitor their response to the treatment. This is an important opportunity for patients with pancreatic cancer to access potentially new therapies and contribute to the understanding of how to better treat this challenging disease.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age: ≥18 years
• • For Phase 1b, histologically or cytologically confirmed pancreatic adenocarcinoma (locally advanced or metastatic) with at least 1 prior therapy in either the advanced or perioperative setting
• • For Phase 1b, measurable disease and/or non-measurable disease per RECIST v1.1
• • For Phase 2, histologically or cytologically confirmed pancreatic adenocarcinoma without evidence of disease progression while receiving initial chemotherapy for metastatic disease (e.g., must have had a demonstrated CR, PR, or SD following initial chemotherapy).
• • For Phase 2, measurable disease and/or non-measurable or no evidence of disease assessed by baseline CT (or MRI where CT is contraindicated). RECIST v1.1 will be used to allow for assessment of disease progression due to new lesions in patients with no evidence of disease at baseline. Patients with no evidence of disease following FOLFIRINOX chemotherapy will be deemed to have radiographic disease progression if new lesions are detected.
• • For Phase 2, treatment with FOLFIRINOX for metastatic pancreatic adenocarcinoma at full or modified doses, for a minimum of 16 weeks, and no evidence of progression based on the radiographic imaging.
• • a. Randomization must occur within 6 weeks of the last dose of chemotherapy.
• • b. Patients who have received at least 16 weeks of FOLFIRINOX combination regimen but had non-fluoropyrimidine chemotherapeutic agents discontinued prior to 16 weeks due to toxicity are eligible if they have no radiographic evidence of disease.
• • For Phase 2, patients who received prior chemotherapy or prior chemoradiation for a prior cancer or as adjuvant/neoadjuvant treatment for pancreatic adenocarcinoma are eligible provided at least 12 months have elapsed between the last dose of treatment and initiation of the FOLFIRINOX chemotherapy for metastatic pancreatic adenocarcinoma.
• • Prior radiation therapy is allowed, provided \>14 days have elapsed since completion of radiation prior to randomization.
• • Adequate organ function
• • ECOG Performance Status 0-1 at the date of signing the informed consent.
• Exclusion Criteria:
• • For Phase 2, radiographic progression of tumor per RECIST 1.1 between start of first line FOLFIRINOX chemotherapy for metastatic pancreatic adenocarcinoma and randomization.
• • Cytotoxic chemotherapy or non-hormonal targeted therapy within 28 days of Cycle 1 Day 1 is not permitted. Palliative radiotherapy must have been completed 14 or more days before Cycle 1 Day 1. The patient can receive a stable dose of bisphosphonates or RANKL directed therapy for bone metastases before and during the study as long as these were initiated at least 2 weeks prior to study treatment
• • For Phase 2, not receiving FOLFIRINOX as initial therapy for metastatic PDAC. Patients who received FOLFIRINOX initially and who needed to discontinue irinotecan or oxaliplatin due to toxicity are eligible, provided they received at least 4 weeks (2 cycles) of FOLFIRINOX
• • For Phase 2, more than 1 prior line of therapy for metastatic PDAC
• • Exposure to an investigational agent within 30 days or 5 half-lives (whichever is longer) prior to randomization
• • Any previous treatment with a HDAC inhibitor, including ivaltinostat